Cell:P53触发氧化应激中的细胞坏死

2012-06-25 mili 生物谷

缺血相关的氧化损伤往往会导致组织坏死,尤其在脑组织,局部产生的氧化应激反应较为剧烈且抗氧化损伤能力弱。因此,阐明氧化损伤的信号通路对于保护机体组织尤为重要。P53蛋白是细胞对于多种类型的损伤产生应答的中心传感器,它能在氧化应激反应中调节细胞的凋亡和自噬,但是氧化应激所导致的细胞坏死是否与P53蛋白有关目前还未有研究报道。本文研究者报道了P53能够在氧化应激中激活细胞坏死途径。 在氧化应激条件下,

缺血相关的氧化损伤往往会导致组织坏死,尤其在脑组织,局部产生的氧化应激反应较为剧烈且抗氧化损伤能力弱。因此,阐明氧化损伤的信号通路对于保护机体组织尤为重要。P53蛋白是细胞对于多种类型的损伤产生应答的中心传感器,它能在氧化应激反应中调节细胞的凋亡和自噬,但是氧化应激所导致的细胞坏死是否与P53蛋白有关目前还未有研究报道。本文研究者报道了P53能够在氧化应激中激活细胞坏死途径。

在氧化应激条件下,P53蛋白能够与线粒体基质中的亲环素D(cyclophilin D,CypD)形成复合物,使线粒体膜通透性转换孔(mitochondrial PTP pore )打开,引起线粒体内容物释放,从而导致细胞坏死。

另外,研究人员还在中风小鼠模型的脑组织坏死区域检测到了P53-CypD复合体。阻止该复合体的形成有助于减少中风的症状。

doi:10.1016/j.cell.2012.05.014

PMC:
PMID:

p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis

Angelina V. Vaseva, Natalie D. Marchenko, Kyungmin Ji, Stella E. Tsirka, Sonja Holzmann, Ute M. Moll

Ischemia-associated oxidative damage leading to necrosis is a major cause of catastrophic tissue loss, and elucidating its signaling mechanism is therefore of paramount importance. p53 is a central stress sensor responding to multiple insults, including oxidative stress to orchestrate apoptotic and autophagic cell death. Whether p53 can also activate oxidative stress-induced necrosis is, however, unknown. Here, we uncover a role for p53 in activating necrosis. In response to oxidative stress, p53 accumulates in the mitochondrial matrix and triggers mitochondrial permeability transition pore (PTP) opening and necrosis by physical interaction with the PTP regulator cyclophilin D (CypD). Intriguingly, a robust p53-CypD complex forms during brain ischemia/reperfusion injury. In contrast, reduction of p53 levels or cyclosporine A pretreatment of mice prevents this complex and is associated with effective stroke protection. Our study identifies the mitochondrial p53-CypD axis as an important contributor to oxidative stress-induced necrosis and implicates this axis in stroke pathology.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868539, encodeId=f3151868539d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 06 14:04:00 CST 2012, time=2012-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958771, encodeId=585b1958e71ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 30 21:04:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362761, encodeId=babb1362e618b, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372342, encodeId=902213e23422f, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445073, encodeId=318414450e34b, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868539, encodeId=f3151868539d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 06 14:04:00 CST 2012, time=2012-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958771, encodeId=585b1958e71ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 30 21:04:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362761, encodeId=babb1362e618b, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372342, encodeId=902213e23422f, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445073, encodeId=318414450e34b, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-09-30 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868539, encodeId=f3151868539d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 06 14:04:00 CST 2012, time=2012-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958771, encodeId=585b1958e71ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 30 21:04:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362761, encodeId=babb1362e618b, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372342, encodeId=902213e23422f, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445073, encodeId=318414450e34b, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-06-27 millore
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868539, encodeId=f3151868539d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 06 14:04:00 CST 2012, time=2012-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958771, encodeId=585b1958e71ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 30 21:04:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362761, encodeId=babb1362e618b, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372342, encodeId=902213e23422f, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445073, encodeId=318414450e34b, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-06-27 zhishijing
  5. [GetPortalCommentsPageByObjectIdResponse(id=1868539, encodeId=f3151868539d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 06 14:04:00 CST 2012, time=2012-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958771, encodeId=585b1958e71ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 30 21:04:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362761, encodeId=babb1362e618b, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372342, encodeId=902213e23422f, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445073, encodeId=318414450e34b, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]

相关资讯

PNAS:蛋白质互作模型或可以提供新的癌症疗法

近日,来自堪萨斯大学的研究者llya Vakser表示,蛋白质并不是多刚体(rigid bodies),它们可以改变形状并且非常灵活,因此我们常常可以将两个完全不匹配的蛋白质进行互相匹配。数年来,科学家依赖于计算机模型技术来表征蛋白质的特征,当然这种精确的计算机模型技术是基于通过X射线晶体学和核磁共振技术来对蛋白质的结构进行模板定位的。 直到现在,这种模板的实际应用价值对于蛋白-蛋白复合物是可用

AJH:冠状动脉疾病的遗传标志物

近日,明尼苏达大学公共卫生研究学院大学发表论文称他们发现了两个冠状动脉疾病(CAD)的遗传标志物,有助于预示罹患该疾病的风险。 这项研究由明尼苏达州公立学校流行病学和社区卫生助理教授Weihong Tang率领研究,相关研究论文发表在American Journal of Human Genetics杂志上。 Tang表示:我们的研究主要针对两个临床常见的血液测试中的不足之处,即APTT试验和

PLoS ONE:GPx3酶有助预防心血管疾病

近日,明尼苏达医学院的研究人员与公共卫生学院合作发现一种酶,该酶在较高水平以及高密度脂蛋白(好胆固醇)水平低时,可以大大降低风险心血管疾病。 这种新发现的酶叫谷胱甘肽过氧化物酶或GPX3,是一种天然抗氧化剂,有助于保护生物体的氧化损伤,有助于机体的自然修复。研究人员发现“好”胆固醇水平高的患者之间,GPX3酶的水平并没有显着性差异。然而,“好”胆固醇水平低的患者,GPX3酶可能对疾病来说是一个益

Mol Pharma:科学家揭示毛地黄可以抵御高血压和心力衰竭

近日,来自密歇根大学健康系统的研究者通过研究发现,一个使用了几个世纪的老药可以在机体的血管中激活一种机体保护机制。这种古老的心脏药物激发了中医的灵感,使得中医们使用这种药物来治疗处于瘟疫人群和过重人群。早在13世纪,有毒的草本植物毛地黄就被用于清理伤口,而且其干叶被用来酿酒以治疗因为心脏问题而导致的腿部肿胀。 这篇刊登在国际杂志Molecular Pharmacology上的研究文章中,研究者揭

Genetics:研究者揭示连接糖尿病和阿尔兹海默症的共同基因

近日,来自纽约城市大学的研究者研究发现,存在于阿尔茨海默症患者机体的基因可以影响其胰岛素途径。这个途径的破坏将会是引发糖尿病的一个标志,相关研究成果刊登在了近日的国际著名杂志Genetics上,这将为开发一些靶向治疗方法提供了线索和希望。 II型糖尿病患者存在高的痴呆风险,胰岛素途径介导了很多代谢过程,包括帮助维持神经系统的健康等等。目前尽管阿尔兹海默症的原因尚不清楚,但是目前患者死后诊断的标准

PLoS ONE:王福俤等人类代谢相关疾病离子组学研究获进展

近日,PLoS ONE在线发表了营养所王福俤研究组、林旭研究组及中科院系统生物学重点实验室李亦学研究组在代谢相关疾病离子组学方面的合作研究成果。 生物体内的离子(包括金属、类金属和非金属)含量及分布具有重要的生理学意义并逐渐成为生命科学的研究热点,离子组学是利用现代高通量元素分析手段如电感耦合等离子质谱(ICP-MS),结合生物信息学和功能基因组学等手段来研究检测样本中的离子含量、分布、转运代谢